Clinical Trials on Metastatic Well Differentiated Neuroendocrine Neoplasm in United States

Total 19408 results

Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Well-differentiated Non-functional NET of Thoracic Origin | Well-differentiated Non-functional NET of Gastrointestinal Origin | Well-differentiated Non-functional NET of Pancreatic Origin | Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

United States, Italy, Spain, Japan, Belgium, Netherlands, Germany, France, Canada, Austria, United Kingdom, Australia
Foundation Medicine
The Cleveland Clinic; Rush University Medical Center; St. Luke's Hospital and... and other collaborators

Completed

Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary

Neoplasms, Unknown Primary | CUP | Metastatic Disease | Poorly Differentiated Adenocarcinoma | Poorly Differentiated Carcinoma | Squamous Carcinoma Poorly Differentiated

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Recruiting

AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm

Carcinoid Syndrome | Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Recruiting

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Neuroendocrine Tumors | High Grade Neuroendocrine Carcinoma, Any Site | Well-Differentiated Neuroendocrine Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Incyte Corporation

Active, not recruiting

Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

Well-differentiated/Dedifferentiated Liposarcoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Metastatic Neuroendocrine Neoplasm | Metastatic Neuroendocrine Carcinoma | Metastatic Large Cell Neuroendocrine Carcinoma | Metastatic Small Cell Neuroendocrine Carcinoma

United States, Canada
National Cancer Institute (NCI)

Recruiting

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Locally Advanced Chondrosarcoma | Metastatic Chondrosarcoma | Metastatic Sinonasal Adenocarcinoma | Locally Advanced Sinonasal Adenocarcinoma | Metastatic Large-cell Neuroendocrine Carcinoma | Locally Advanced Large-cell Neuroendocrine Carcinoma | Metastatic Olfactory Neuroblastoma | Locally Advanced... and other conditions

United States
Jazz Pharmaceuticals

Completed

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201) (EMERGE-201)

Advanced Solid Tumor | Metastatic Solid Tumor | Urothelial Cancer | Poorly Differentiated Neuroendocrine Carcinomas | Homologous Recombination Deficient-Positive Malignancies Agnostic

United States
M.D. Anderson Cancer Center
TerSera Therapeutics LLC

Recruiting

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

Locally Advanced Neuroendocrine Neoplasm | Metastatic Neuroendocrine Neoplasm

United States
National Cancer Institute (NCI)

Terminated

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

Thyroid Neoplasms | Differentiated Thyroid Cancer | Poorly Differentiated and Undifferentiated Thyroid Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Metastatic Digestive System Neuroendocrine Neoplasm | Metastatic Neuroendocrine Tumor

United States
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)

Terminated

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

Metastatic Cancer | Metastatic Melanoma

United States
The Christie NHS Foundation Trust
Pancreatic Cancer UK

Completed

Pancreatic Cancer Dietary Assessment Study (PanDA)

Pancreas Adenocarcinoma | Pancreatic Neoplasm | Malignant Neoplasm of Pancreas | Well-Differentiated Neuroendocrine Carcinoma

United Kingdom
Fred Hutchinson Cancer Center
Incyte Corporation

Terminated

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Refractory Soft Tissue Sarcoma | Metastatic Leiomyosarcoma | Metastatic Synovial Sarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Advanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Advanced Synovial Sarcoma | Metastatic Chondrosarcoma | Advanced Leiomyosarcoma | Metastatic Myxoid... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Metastatic Midgut Neuroendocrine Tumor | Unresectable Midgut Neuroendocrine Tumor | Metastatic Midgut Neuroendocrine Tumor G1 | Metastatic Midgut Neuroendocrine Tumor G2

United States, Canada
National Cancer Institute (NCI)

Recruiting

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Locally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa)

Recurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Metastatic Angiosarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Recurrent Angiosarcoma | Refractory Dedifferentiated Liposarcoma

United States
Nicholas Fidelman, MD
Merck Sharp & Dohme LLC; BTG International Inc.

Active, not recruiting

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver

United States
Vanderbilt-Ingram Cancer Center

Recruiting

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Metastatic Digestive System Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2 | Digestive System Neuroendocrine Tumor G1 | Digestive System Neuroendocrine Tumor G2

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Metastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Metastatic Breast Carcinoma | Metastatic Ovarian Cancer | Metastatic Endocrine Tumors/ Neuroendocrine Tumors

United States
Pfizer

Completed

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Well-differentiated Pancreatic Neuroendocrine Tumor

United States, China, Czechia, India, Japan, South Africa, Slovakia, France, Norway, Romania, Australia, Belgium, Hungary, Italy, Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

Undifferentiated Pleomorphic Sarcoma | Recurrent Undifferentiated Pleomorphic Sarcoma | Dedifferentiated Liposarcoma | Resectable Dedifferentiated Liposarcoma | Resectable Undifferentiated Pleomorphic Sarcoma | Recurrent Dedifferentiated Liposarcoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Meningioma | Neuroendocrine Neoplasm | Multiple Endocrine Neoplasia Type 1 | Von Hippel-Lindau Syndrome | Metastatic Well Differentiated Neuroendocrine Neoplasm | Somatostatin Positive Neoplastic Cells Present

United States
University of Pennsylvania

Completed

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

Metastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid Cancer

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

Neuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors

United States
Peter Anderson

Completed

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Metastatic Neuroendocrine Tumor | Recurrent Neuroendocrine Tumor

United States
National Cancer Institute (NCI)

Terminated

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Metastatic Cancer | Metastatic Melanoma | Metastatic Renal Cell Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Neuroendocrine Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Perception of Cure Among Patients With Metastatic Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Completed

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Carcinoid Tumor | Neuroendocrine Neoplasm | Metastatic Carcinoid Tumor

United States
Dwight Owen
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Neuroendocrine Tumors | Small-cell Lung Cancer | Neuroendocrine Carcinoma | Large Cell Neuroendocrine Carcinoma | Lung Cancer Stage IV | Recurrent Small Cell Lung Carcinoma | Refractory Small Cell Lung Carcinoma | Metastatic Neuroendocrine Carcinoma | Grade I Neuroendocrine Carcinoma | Grade II Neuroendocrine... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer

Metastatic Cancer | Metastatic Melanoma | Metastatic Renal Cancer

United States
National Cancer Institute (NCI)

Terminated

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Metastatic Cancer | Metastatic Melanoma | Metastatic Renal Cancer

United States
Roswell Park Cancer Institute
Ipsen

Active, not recruiting

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

Unresectable Pancreatic Neuroendocrine Carcinoma | Locally Advanced Digestive System Neuroendocrine Carcinoma | Locally Advanced Pancreatic Neuroendocrine Carcinoma | Metastatic Digestive System Neuroendocrine Carcinoma | Metastatic Pancreatic Neuroendocrine Carcinoma | Refractory Digestive... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

Sarcoma | Soft Tissue Sarcoma | Sarcoma,Soft Tissue | Dedifferentiated Liposarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Unresectable Dedifferentiated Liposarcoma

United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Completed

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

Neuroendocrine Tumors | Metastatic Neuroendocrine Tumors

United States
Louisiana State University Health Sciences Center...
Novartis

Completed

Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors (PTK787)

Metastatic Neuroendocrine Tumors

United States
Excel Diagnostics and Nuclear Oncology Center

Withdrawn

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. (PUTNET)

Neuroendocrine Tumors | Pheochromocytoma | Paraganglioma | Unknown Primary Tumors | Pulmonary Neuroendocrine Neoplasm | Thymus Carcinoid | Neuroendocrine Skin Carcinoma | Neuroendocrine Breast Tumor | Neuroendocrine Carcinoma Metastatic | Neuroendocrine Neoplasm of Ovary

United States
University of Washington
Eli Lilly and Company

Recruiting

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Metastatic Digestive System Neuroendocrine Neoplasm | Pancreatic Neuroendocrine Tumor | Advanced Digestive System Neuroendocrine Neoplasm | Digestive System Neuroendocrine Tumor | Foregut Neuroendocrine Tumor | Hindgut Neuroendocrine... and other conditions

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Accuray Incorporated

Completed

SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine

Stage IV Skin Melanoma | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the Spine

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Spine

United States
Roswell Park Cancer Institute

Not yet recruiting

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors

Malignant Solid Neoplasm | Lung Neuroendocrine Neoplasm | Digestive System Neuroendocrine Neoplasm | Pancreatic Neuroendocrine Neoplasm

United States
University of Michigan Rogel Cancer Center

Recruiting

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Metastatic Melanoma | Liver Metastases | Melanoma, Mucosal | Melanoma, Ocular | Melanoma, Cutaneous

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma | Castration-Sensitive Prostate Carcinoma

United States
Mohammed M Milhem
Genentech, Inc.

Terminated

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (ML28604)

Melanoma | Metastatic Melanoma | BRAF-mutated Metastatic Melanoma | V600EBRAF-mutated Metastatic Melanoma

United States
University of Arizona

Completed

Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors

Melanoma | Renal Cell Carcinoma | HCC | Hepatocellular Carcinoma | Metastatic Cancer | Metastatic Melanoma | Colon Cancer | Differentiated Thyroid Cancer | Metastatic Colon Cancer

United States
M.D. Anderson Cancer Center

Active, not recruiting

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma | Castration-Resistant...

United States
National Cancer Institute (NCI)

Recruiting

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Metastatic Neuroendocrine Tumor

United States

Clinical Trials on Metastatic Well Differentiated Neuroendocrine Neoplasm in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations